Pharmaron Beijing Co., Ltd. Overview
Pro stress-test →Pharmaron Beijing is a comprehensive pharmaceutical research and development service provider founded in 2004, offering full-spectrum drug discovery, development, and manufacturing services. The company serves pharmaceutical and biotechnology clients globally, spanning small molecule drugs, cell therapies, and gene therapies across multiple geographic markets.
Strategic Profile
Pro stress-test →Pharmaron operates as a full-service CDMO and CRO with integrated capabilities spanning laboratory services, chemical and formulation development, clinical research, and macromolecule/cell & gene therapy services. The company's diversified service portfolio and global footprint position it as a key enabler for biotech innovation, with particular strength in emerging therapies like ADCs and gene therapies.
Competitive Landscape
Pro stress-test →Pharmaron competes in the CDMO/CRO space alongside global players like Wuxi AppTec, Asymchem, and international firms (Thermo Fisher, Charles River), as well as emerging Chinese providers. Its competitive differentiation centers on integrated full-service capabilities, emerging therapy expertise (ADCs, cell/gene therapy), and established client relationships across pharma's innovation pipeline.
Industry Context
Pharmaron Beijing Co., Ltd. operates in Pharmaceutical Research and Development Services (CDMO/CRO).
Key facts
Founded: 2004 · Headquarters: Beijing, China · Employees: 21,370 · Revenue: $1.7B · Market cap: $7.1B